Relapsed or Refractory Myelodysplastic Syndrome Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
DelveInsight’s, “Relapsed or Refractory Myelodysplastic Syndrome Pipeline Insight 2023” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Relapsed or Refractory Myelodysplastic Syndrome pipeline landscape. It covers the Relapsed or Refractory Myelodysplastic Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Relapsed or Refractory Myelodysplastic Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Relapsed or Refractory Myelodysplastic Syndrome Pipeline Report
- DelveInsight’s Relapsed or Refractory Myelodysplastic Syndrome pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Relapsed or Refractory Myelodysplastic Syndrome treatment.
- The leading companies working in the Relapsed or Refractory Myelodysplastic Syndrome Market include Cantex Pharmaceuticals, Novartis, Newave Pharmaceuticals, BioTheryX, Agios Pharmaceuticals, and others.
- Promising Relapsed or Refractory Myelodysplastic Syndrome Pipeline Therapies in the various stages of development include CX-01, Azacitidine, SyB C-1101, NC525, LP-108, CC-91633, Talacotuzumab, Daratumumab, CC-90009, BTX-A51, and others.
- November 2023: NextCure Inc. announced a study of Phase 1 clinical trials for NC525. This is an open-label, non-randomized, Phase 1 study to determine the safety and tolerability of NC525. This study will also assess the clinical benefit in subjects with advanced myeloid neoplasms. A Phase 1, Open-Label, Safety, Tolerability, and Efficacy Study of NC525 in Subjects with Advanced Myeloid Neoplasms.
- October 2023: Celgene announced a study of Phase 1 clinical trials for CC-91633. A Phase 1, Open-label, Dose-finding Study of CC-91633 (BMS-986397) in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes.Study CC-91633-AML-001 is a Phase 1, open-label, dose escalation and expansion, first-in-human (FIH) clinical study of CC-91633 (BMS-986397) in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myelodysplastic syndromes (R/R HR-MDS). The Dose Escalation part (Part A) of the study will enroll participants with R/R AML and R/R HR-MDS and will evaluate the safety and tolerability of escalating doses of CC-91633 (BMS-986397), administered orally, and determine the maximum tolerated dose (MTD) or preliminary recommended Phase 2 dose (RP2D) and schedule.
- October 2023: Thomas Jefferson University announced a study of Phase 1 & 2 clinical trials for Venetoclax and Decitabine. This phase Ib/II trial tests the safety, side effects, and best dose of navitoclax in combination with venetoclax and decitabine in treating patients with higher risk myelodysplastic syndrome (MDS) that has come back after initial treatment or was not responsive to initial treatment. This study will also look at the effectiveness of the treatment combination and patient’s quality of life while on these medications. Navitoclax is an oral drug that works as an inhibitor of the BCL-2 family of proteins, which are often overly expressed in a wide variety of cancers and are linked to tumor drug resistance. This drug blocks some of the enzymes that keep cancer cells from dying. Venetoclax is an oral drug that works as an inhibitor of BCL-2 proteins that works very similarly to navitoclax by blocking the action of a certain proteins in the body that helps cancer cells survive which helps to kill cancer cells.
- October 2023: M.D. Anderson Cancer Center announced a study of Phase 1 & 2 clinical trials for Akt/ERK Inhibitor ONC201. This phase I/II trial studies the side effects and best dose of ONC201 and to see how well it works in treating patients with acute leukemia or high-risk myelodysplastic syndrome that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). ONC201 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Request a sample and discover the recent advances in Relapsed or Refractory Myelodysplastic Syndrome Treatment Drugs @ Relapsed or Refractory Myelodysplastic Syndrome Pipeline Report
In the Relapsed or Refractory Myelodysplastic Syndrome pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Relapsed or Refractory Myelodysplastic Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Relapsed or Refractory Myelodysplastic Syndrome Overview
Myelodysplastic syndromes (MDS) are defined by ineffective hematopoiesis resulting in blood cytopenias, and clonal instability with a risk of clonal evolution to acute myeloid leukemia (AML).Patients with MDS collectively have a high symptom burden and are also at risk of death from complications of cytopenias and AML3.
Find out more about Relapsed or Refractory Myelodysplastic Syndrome Therapeutics Assessment @ Relapsed or Refractory Myelodysplastic Syndrome Preclinical and Discovery Stage Products
Relapsed or Refractory Myelodysplastic Syndrome Emerging Drugs Profile
- CX-01: Cantex Pharmaceuticals
- LP-108: Newave Pharmaceuticals
- BTX-A51: BioTheryX
Relapsed or Refractory Myelodysplastic Syndrome Pipeline Therapeutics Assessment
There are approx. 5+ key companies which are developing the Relapsed or Refractory Myelodysplastic Syndrome therapies. The Relapsed or Refractory Myelodysplastic Syndrome companies which have their Relapsed or Refractory Myelodysplastic Syndrome drug candidates in the mid to advanced stage, i.e. Phase II include, Cantex Pharmaceuticals and others.
DelveInsight’s Relapsed or Refractory Myelodysplastic Syndrome Pipeline report covers around 5+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Relapsed or Refractory Myelodysplastic Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Subcutaneous
- Intravenous
- Oral
- Intramuscular
- Parenteral
- Molecule Type
Relapsed or Refractory Myelodysplastic Syndrome Pipeline Products have been categorized under various Molecule types such as
- Small molecules
- Polymer
- Peptide
- Gene Therapy
- Monoclonal antibodies
- Product Type
Learn more about the emerging Relapsed or Refractory Myelodysplastic Syndrome Pipeline Therapies @ Relapsed or Refractory Myelodysplastic Syndrome Clinical Trials Assessment
Scope of the Relapsed or Refractory Myelodysplastic Syndrome Pipeline Report
- Coverage- Global
- Relapsed or Refractory Myelodysplastic Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Relapsed or Refractory Myelodysplastic Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Relapsed or Refractory Myelodysplastic Syndrome Companies- Cantex Pharmaceuticals, Novartis, Newave Pharmaceuticals, BioTheryX, Agios Pharmaceuticals, and others.
- Relapsed or Refractory Myelodysplastic Syndrome Pipeline Therapies- CX-01, Azacitidine, SyB C-1101, NC525, LP-108, CC-91633, Talacotuzumab, Daratumumab, CC-90009, BTX-A51, and others.
Dive deep into rich insights for new drugs for Relapsed or Refractory Myelodysplastic Syndrome Treatment, Visit @ Relapsed or Refractory Myelodysplastic Syndrome Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Relapsed or Refractory Myelodysplastic Syndrome: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Relapsed or Refractory Myelodysplastic Syndrome – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Relapsed or Refractory Myelodysplastic Syndrome Collaboration Deals
- Late Stage Products (Phase III)
- AG-120: Agios Pharmaceuticals
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- CX-01: Cantex Pharmaceuticals
- Drug profiles in the detailed report…..
- Early-Stage Products (Phase I)
- BTX A51: BioTheryX
- Drug profiles in the detailed report…..
- Inactive Products
- Relapsed or Refractory Myelodysplastic Syndrome Key Companies
- Relapsed or Refractory Myelodysplastic Syndrome Key Products
- Relapsed or Refractory Myelodysplastic Syndrome- Unmet Needs
- Relapsed or Refractory Myelodysplastic Syndrome- Market Drivers and Barriers
- Relapsed or Refractory Myelodysplastic Syndrome- Future Perspectives and Conclusion
- Relapsed or Refractory Myelodysplastic Syndrome Analyst Views
- Relapsed or Refractory Myelodysplastic Syndrome Key Companies
- Appendix
For further information on the Relapsed or Refractory Myelodysplastic Syndrome Pipeline therapeutics, reach out to Relapsed or Refractory Myelodysplastic Syndrome Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/relapsed-or-refractory-myelodysplastic-syndrome-market
){kind=link}